Cargando…
Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions
Adjuvant hormonal therapy for postmenopausal women with early stage breast cancer has become far more complex over the past several years. This commentary reviews the current status of the five major trials evaluating the use of the aromatase inhibitors in the adjuvant setting. The data currently av...
Autores principales: | Ligibel, Jennifer A, Winer, Eric P |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1410766/ https://www.ncbi.nlm.nih.gov/pubmed/16457700 http://dx.doi.org/10.1186/bcr1347 |
Ejemplares similares
-
Direct or indirect endothelial damage? An unresolved question
por: Basta, Giuseppina
Publicado: (2021) -
Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer
por: Chen, Han, et al.
Publicado: (2020) -
Mitochondrial dysfunction in aging: Much progress but many unresolved questions
por: Payne, Brendan A.I., et al.
Publicado: (2015) -
C5 Inhibition in Secondary Thrombotic Microangiopathies: A Yet Unresolved Question
por: Werion, Alexis, et al.
Publicado: (2021) -
Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update
por: Mokbel, Ramia, et al.
Publicado: (2006)